Overview
Myriad Genetics Q3 2025 revenue declines 4% yr/yr, beats analyst expectations
Adjusted operating income for Q3 beats analyst estimates
Company recently entered into strategic collaboration with SOPHiA GENETICS for liquid biopsy CDx testing
Outlook
Myriad Genetics reaffirms full-year 2025 revenue guidance of $818 mln to $828 mln
Gross margin for 2025 expected between 69.5% and 70.0%
Adjusted EPS for 2025 projected between $(0.02) and $0.02
Result Drivers
HEREDITARY CANCER GROWTH - Hereditary cancer testing revenue and volume grew 3% and 11% yr/yr, respectively
STRATEGIC COLLABORATION - Entered collaboration with SOPHiA GENETICS to develop liquid biopsy CDx testing solution
PHARMACOGENOMICS DECLINE - Revenue impacted by UnitedHealthcare's discontinuation of coverage for GeneSight
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $205.70 mln | $204.89 mln (13 Analysts) |
Q3 Adjusted EPS | -$0.00785 (13 Analysts) | ||
Q3 EPS | -$0.29 | ||
Q3 Net Income | -$27.40 mln | ||
Q3 Gross Margin | 69.90% | ||
Q3 Adjusted Operating Income | Beat | $4.10 mln | $133,130 (8 Analysts) |
Q3 Adjusted Operating Expenses | $140 mln | ||
Q3 Operating Expenses | $167.10 mln | ||
Q3 Operating Income | -$23.30 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 8 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Myriad Genetics Inc is $6.50, about 23.7% below its October 31 closing price of $8.04
The stock recently traded at 99 times the next 12-month earnings vs. a P/E of 51 three months ago
Press Release: ID:nGNXbqW5TY
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)